Inclusion Criteria:

- Diagnosis of symptomatic multiple myeloma as defined by International Myeloma Working
Group (IMWGURC).

- Phase 1: Relapsed or relapsed/refractory myeloma after at least 1 previous treatments
and with a life expectancy of more than 3 months.

- Phase 2: Measurable (as defined by IMWGURC) disease after at least 1 previous
treatment.

Exclusion Criteria:

- History of allogeneic stem cell transplant.

- Phase 2 only: Prior bortezomib therapy will only be allowed if there was a
demonstrated positive response, and disease progression occurred off therapy.

- Must have not experienced significant blood level changes, e.g. very low platelets,
while on previous bortezomib therapy

- Prior radiation therapy to > 25% of the bone marrow (whole pelvis is 25%).